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Abstract 
Background: Catheter directed thrombolysis (CDT) and thrombectomy represent well 
established techniques for the treatment of intermediate pulmonary embolism (IPE). The 
long-term effect of catheter directed thrombolysis of IPE is unknown.  
Methods: Clinical, interventional and echocardiographic data from 80 consecutive patients 
with IPE who were treated with CDT were evaluated. Primary end-points were technical 
success and major adverse events (MAEs). Secondary end-points were cardiovascular 
mortality, all-cause mortality, clinical success, rate of bleeding complications, improvement 
in pulmonary pressure and echocardiography parameters. CDT completed with alteplase (10 
mg bolus and 1 mg/h maintenance dose) through a pig-tail catheter for 24 h. After 24 h, 
control pulmonary angiography was performed.  
Results: In total, 80 patients with a mean age of 59.0 ± 16.8 years were treated. CDT was 
successful after the first post-operative day in 72 (90%) patients, but thrombus aspiration and 
fragmentation was performed due to failed thrombolysis in 8 (10%) patients. Final technical 
and clinical success was reached in 79 (98.8%) and 77 (96.3%) patients, respectively. The 
mean CDT time in IPE was 27.8 ± 9.6 h. Invasive pulmonary pressure dropped from 57.5 ± 
16.7 to 38.9 ± 13.5 (p < 0.001). A caval filter was implanted in 4 (5%) patients. The 1-year 
MAE and cardiovascular mortality rate was 4.0% and 1.4%, respectively. Access site 
complications (6 major and 6 minor) were encountered in 12 (16.2%) patients. 
Conclusions: Catheter directed thrombolysis in submassive pulmonary embolism had 
excellent results. However, additional mechanical thrombectomy was necessary in some 
patients to achieve good clinical outcomes.  
Key words: pulmonary embolism, local thrombolysis 
 
 
INTRODUCTION 
Venous thromboembolic disease is an underdiagnosed disease spectrum with a high 
mortality and morbidity rate. Recent advances in interventional cardiology, 
pharmacotherapeutics and modern surgical management in tertiary cardiac care centers have 
tremendously improved the present treatment of pulmonary embolism (PE). PE is commonly 
classified as high-risk, intermediate-risk, and low-risk to help determine the required 
treatment [1]. Despite recent advances in mechanical thrombectomy (MT) and catheter 
directed thrombolysis (CDT), the primary treatment is systemic thrombolysis (ST) in 
intermediate- and high-risk pulmonary embolism [1]. ST is associated with a high rate of 
recanalization in intermediate PE (IPE), but bleeding complications are very frequent and 
hazardous [2]. Despite recent advances in IPE, MT and CDT have a IIb indication in the 
recent European and American College of Cardiology guidelines [1, 2]. When thrombolysis is 
contraindicated or has failed, urgent surgical embolectomy or catheter embolectomy may be 
lifesaving procedures in high-risk PE. The aim of the study was to investigate the safety and 
efficacy of CDT and MT in intermediate PE and to investigate the long-term effects on 
functional status and pulmonary pressure.   
 
METHODS 
Clinical, interventional and echocardiographic data from 80 consecutive patients with 
IPE who were treated with CDT were evaluated. Diagnosis was made by computed 
tomography or pulmonary angiography and transthoracic ultrasound.  
Inclusion criteria were: intermediate pulmonary embolism (defined as normotensive 
patients with PE and evidence of right ventricular dysfunction) and patients who underwrote 
the patient form.  
Exclusion criteria were: contraindications for the local administration of thrombolytic 
therapy (stroke or transient ischemic attack, head trauma, or other active intracranial or 
intraspinal disease within 12 months; major surgery within 7 days; recent active bleeding 
from a major organ); and massive PE (defined as syncope, systemic arterial hypotension, 
cardiogenic shock, or resuscitated cardiac arrest).  
Primary end-points were: technical success and major adverse events (MAEs). 
Secondary end-points were: all-cause mortality, cardiovascular mortality, clinical 
success, rate of bleeding complications, improvement in pulmonary pressure, blood gas 
analysis, and echocardiography parameters.  
 
Procedure description 
The access site for CDT was the contralateral femoral vein. The common femoral vein 
was punctured in a regular fashion, but in vascular cases, vascular ultrasound guidance was 
used when the puncture was difficult. Pulmonary angiography and invasive pulmonary 
pressure measurement were performed before CDT (Fig. 1A). CDT was done with alteplase 
(10 mg bolus and 1 mg/h maintenance dose) through a pig-tail catheter for 24 h. After 24 h, 
control pulmonary angiography and invasive pressure measurement was done (Fig. 1B). 
During the procedure, intravenous unfractionated heparin was continued at intermediate 
intensity with a goal activated partial thromboplastin time of 40–60 s. MT was performed 
when the thrombus burden was flow limiting or the systolic pulmonary pressure had not 
decreased by 25% or to the normal level (Fig. 2A). Thrombus fragmentation with the pigtail 
catheter was done in cases of extreme flow limiting thrombus. Thrombus aspiration was done 
with a 7 F guiding catheter and long 7 F sheath using a 50-mL syringe for manual aspiration 
(Fig. 2B). After removal of the catheters, the access site was manually compressed for a 
minimum of 5 min. Insertion of inferior vena cava (IVC) filters was discouraged unless the 
patient developed a contraindication to therapeutic-dose systemic anticoagulation or if the 
patient suffered recurrent PE despite therapeutic levels of anticoagulation. Postoperatively, 
patients were treated with systemic anticoagulation and compression hose, and follow-up was 
completed at specified intervals. 
Pulmonary angiography with digital subtraction was done on the next postoperative 
day in all patients. Thrombus burden was categorized as: occlusive or large (75–100% of the 
lumen) (Grade 3), medium (50–75% of the lumen) (Grade 2), small (0–50% of the lumen) 
(Grade 1) or no visible thrombus (Grade 0).  
Twelve-lead electrocardiography was done in all patients at admission and before 
discharge.  
Transthoracic ultrasound was performed before and after thrombolytic therapy. 
Routine right heart measurements were performed to investigate right ventricular function. 
 
Post procedural follow-up 
Access arteries were investigated physically after the procedure. All patients 
underwent detailed clinical follow-up examinations at two and 12 months after the procedure. 
 
Definitions 
Pulmonary hypertension was quantified by systolic pulmonary artery pressure as 
normal (< 40 mmHg), mild hypertension (“40–60” > 90 mmHg), moderate hypertension (“60–
90” > 90 mmHg) and severe hypertension (> 90 mmHg) [3]. 
Major adverse events were assessed as the composite of cardiovascular death, 
myocardial infarction, stroke, and repeated revascularization of the target vessel by surgical 
thrombectomy at two months and twelve months.  
Bleeding events were classified by the Global Utilization of Streptokinase and Tissue 
Plasminogen Activator for Occluded Coronary Arteries (GUSTO) bleeding criteria [3]; major 
bleeding was defined as either GUSTO moderate or GUSTO severe/life-threatening bleeding 
events.  
A major vascular access complication was defined as a diminished or lost arterial 
pulse or the presence of any pseudoaneurysm or arteriovenous fistula during clinical follow-
up. A minor complication was defined as a hematoma requiring no further treatment that 
measures at least “ 5” cm in diameter at the femoral puncture site. Major bleeding was 
defined as a fall in hemoglobin of more than 3 gm/dL or any bleeding requiring a blood 
transfusion. 
A technical success was when the invasive pulmonary pressure decreased by 25% and 
there was no clot in the main pulmonary branch.  
Primary technical success was defined as the moment when CDT reached the end 
points, and secondary technical success was defined as the moment when CDT was followed 
by MT  
Clinical success was an improvement in at least one clinical category of the New York 
Heart Association classification.  
 
Statistical analysis 
Statistical analysis was performed using commercially available Graph Pad Prism 8.0 
software (USA). Each continuous variable was expressed as the mean ± standard deviation or 
as the median (interquartile range), as appropriate. Each categorical variable was expressed as 
a percentage. The various patient cohorts were compared using either the Mann-Whitney test 
or the Kruskal-Wallis test. Probability values not exceeding 0.05 were considered significant. 
 
RESULTS 
In total, 80 patients with submassive and massive pulmonary embolism were treated 
with CDT and MT. Demographic and clinical data and etiology of the pulmonary emboli are 
summarized in Table 1.  
Angiographic and procedural results are summarized in Table 2.  
In total, 80 patients with a mean age of 59 ± 16.8 years were treated. CDT was 
successful after the first post-operative day in 72 (90%) patients, but thrombus aspiration and 
fragmentation was performed due to failed thrombolysis in 8 (10%) patients. Final technical 
and clinical success was reached in 79 (98.8%) and 77 (96.3%) patients, respectively. The 
mean CDT time in IPE was 27.8 ± 9.6 h. The pulse rate and systolic blood pressure at 
presentation was 104.4 ± 17.62 bpm and 128.9 ± 18.7 mmHg, respectively. Invasive 
pulmonary pressure dropped from 57.5 ± 16.7 to 39.9 ± 13.3 and finally to 38.9 ± 13.5 (p < 
0.001). Pre- and post-procedural pulmonary pressure is summarized in Figure 3. A caval filter 
was implanted in 4 (5%) patients. Two patients received it in the acute phase (2.5%): one due 
to large iliac vein thrombosis and the other one due to recurrent pulmonary embolism with 
decreased pulmonary reserve. During follow up caval filter was implanted also in 2 (2.5%) 
patients. The indication was in both patient’s contraindication of oral anticoagulation due to 
major bleeding under post-procedural oral anticoagulation therapy (one gynecological and 
one cerebral focus). 
Echocardiographic parameters are summarized in Table 3.  
All patients had pre-procedural elevated right ventricular systolic pressure (55 46–66 
mmHg), but due to left ventricular enlargement the typical D sign was not present in 4 
patients (5.0%). D sign was post-procedural not present in 93.8% and during follow-up in 
95.0% of the patients. Tricuspid annular plane systolic excursion and pulmonary pressure has 
been improved after CDT and MT from 18 [16–20] to 22 [20–24] mm (p = 0.005) and from 
55 46–66 to 40 40–48 mmHg (p  0.001), respectively.  
Procedural complications are summarized in Table 4.  
As indicated in Table 3, intraprocedural complications were not observed. Worsening 
heart failure or renal failure was not detected in the investigated population. The rates of 
major and minor vascular access complications were 7.5% (4 major subcutaneous hematomas 
and 2 retroperitoneal hematomas) and 7.5% (6 subcutaneous hematomas), respectively.  
 
One-year follow-up  
Clinical success at discharge was reached in 77 (96.2%) patients. The 1-year MAE and 
cardiovascular mortality rates were 4% and 1.4%, respectively. The overall 1-year mortality 
rate was 6.7% (1 cardiovascular and 5 tumor-associated).  
 
DISCUSSION 
According to available research, this study is the first to show long-term clinical 
benefit in patients who underwent CDT and MT in IPE through long-term analysis.  
Systemic full dose thrombolysis in a recent meta-analysis reduced the risk for death 
and cardiovascular collapse but increased the risk for major bleeding and hemorrhagic stroke 
[4]. The PEITHO study was a randomized, double blind study of 1,005 submassive PE 
patients comparing the thrombolytic agent tenecteplase with heparin to a placebo with heparin 
[5]. Death or hemodynamic decompensation occurred within 7 days from randomization in 
2.6% of the patients in the tenecteplase group compared to 5.6% in the placebo group. 
However, stroke occurred in 2.4% in the tenecteplase group compared to 0.2% in the placebo 
group. The long-term follow-up in the PEITHO study showed no survival (98.3% vs. 98%) or 
functional (36% vs. 20.1%) or echocardiographic benefit in the thrombolysis arm compared 
with the anticoagulation arm [6].  
Catheter interventions using thrombolytic drugs include CDT and 
pharmacomechanical thrombolysis. Their application was introduced due to a high rate of 
bleeding events during systemic thrombolysis. The principal mechanism of transcatheter 
therapy is to either dissolve and/or directly remove the clot with direct thrombus aspiration, 
fragmentation, administration of local thrombolytic drug or combination of these 
mechanisms. Thrombus removal is applied to immediately restore blood flow to pulmonary 
circulation, with subsequent improvement in the right ventricular strain, hemodynamic status, 
and oxygenation. Today, the choice lies between streptokinase, recombinant tissue 
plasminogen activator and urokinase. The choice of procedure and tools differs based on the 
severity of the PE and estimated bleeding risk [10]. There are only a few prospective clinical 
trials examining CDT alone [7–9], ultrasound facilitated CDT [11, 12] or CBT with thrombus 
fragmentation and/or mechanical thrombectomy [12] in the setting of intermediate-risk PE, 
but a head to head comparison of different techniques remains non-existant.  
The main advantages of CDT are simplicity, high effectiveness and relatively low 
bleeding risk. The goal for CDT is to achieve similar efficacy to systemic thrombolysis and 
potentially decrease the rate of major and intracranial bleeding by delivering a significantly 
lower dose of thrombolytic drug directly into the thrombus over an extended period of time 
(12–24 h) through a pig-tail or dedicated thrombolytic catheter. The MAPPET-3 trial was the 
first CDT controlled trial in submassive PE using 100 mg alteplase + heparin or heparin only. 
The incidence of in-hospital mortality was significantly higher in the heparin-plus-placebo 
group than in the heparin plus alteplase group (p = 0.006), and the probability of 30-day 
event-free survival was higher in the heparin-plus-alteplase group (p = 0.005) [7]. The 
MOPETT study was a randomized controlled trial of 121 patients comparing ‘safe dose’ 
thrombolytic (half of the full dose) with anticoagulation and an anticoagulation only group. 
Pulmonary artery pressures were significantly lower after 48 h in the thrombolytic group than 
in the anticoagulation group (16 vs. 10 mmHg reduction, p < 0.001) [8]. In a recent 
publication by Carrmona SA, local low-dose urokinase thrombolysis was done in submassive 
PE and an initially high pulmonary artery pressure after CTD (systolic 52.4 vs. 35.2 [17.2, 
95% CI 14.5–19.9]), and follow-up ultrasound showed improvement in right ventricular 
dysfunction. No life-threatening hemorrhagic complications were reported. The 6-month 
survival was 96.5% [9]. The present study shows similar results, but the primary end-point 
was reached only in 90% of patients with CDT, and additional thombectomy was done in 
9.6% of the patients to achieve the primary end-point, which was reached finally in 100% of 
the patients.  
The main disadvantages of CDT are still the high bleeding risk [10] and the limited 
effectiveness of the thrombolytic drug in old thrombi. Bleeding can be puncture related or due 
to the systemic effect of the thrombolytic drug. Puncture related complications can be reduced 
by ultrasound assisted femoral vein puncture [15]; however, in the current study population, 
traditional femoral vein puncture was used, and the rate of access site bleeding was relatively 
high. Periprocedural major bleeding (intracerebral or gastrointestinal) was not observed; 
however, 2 patients had major cerebral bleeding at the 1-year follow-up after initiation of 
novel anticoagulants. The results of a recent meta-analysis of 35 interventional and 
observational (“real world”) studies on CDT calculated a pooled rate of 6.6% for major 
bleeding, with a 3.9% major bleeding and 2.6% in hospital mortality rate in the “stable 
hemodynamic status” group [16]. 
 Pharmacomechanical thrombolysis 
Ultrasound accelerated thrombolysis can be more effective than simple local 
thrombolysis and can reduce the bleeding complications, but a head to head comparison has 
not been done comparing the two techniques. The phase 2 ULTIMA (Ultrasound Accelerated 
Thrombolysis of Pulmonary Embolism) trial randomized 59 patients with acute main- or 
lower-lobe PE and an echocardiographic right-to-left ventricular dimension ratio of 1.0 to 
receive unfractionated heparin plus a catheter-directed, ultrasound-assisted thrombolytic 
regimen of 10 to 20 mg recombinant tissue plasminogen activator over 15 h, as opposed to 
heparin alone. Reduced-dose local thrombolysis significantly reduced the subannular right-to-
left ventricular dimension ratio between the baseline and a 24-h follow-up without an increase 
in bleeding complications [11]. The PERFECT registry, which also lacked a control arm, 
included 101 patients with high-risk and intermediate-risk PE. There were no major or 
intracranial bleeding events with CDT [14].  
Aspiration thrombectomy is a new treatment method and is the rational choice to 
aspirate thrombi from the vascular bed without using a thrombolytic. The potential 
complication is the distal embolization and pulmonary artery trauma, and the effectiveness is 
not well known. MT can be done with dedicated devices or with a simple guiding catheter 
[12]. In the present study group, aspiration thrombectomy was applied in 12 patients with a 
100% technical and 90% clinical success without escalation of major bleeding events.  
 
Limitations of the study 
The main limitation of the study is the lack of a randomized control arm. Another 
limitation is that right heart catheterization was not performed in the patient after the 1-year 
follow-up. 
 
CONCLUSIONS 
Catheter directed thrombolysis in submassive PE had excellent results. However, 
additional mechanical thrombectomy and angioplasty was necessary in several patients to 
achieve a good clinical outcome. 
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Table 1. Demographic data. 
Age [years] 
Female 
Hypertension 
Hyperlipidemia 
Diabetes mellitus 
Obesity 
Active smokers 
Coronary artery disease 
Peripheral artery disease 
Renal failure 
Positive family history (PE) 
59.0 ± 16.8  
38 (47.5%) 
50 (62.5%) 
39 (48.8%) 
7 (8.8%) 
16 (20.0%) 
4 (5.1%) 
3 (3.8%) 
4 (5.0%) 
18 (22.5%) 
2 (2.5%) 
Causes of the deep venous thrombosis and PE 
Idiopathic 
Tumor  
Oral anticonceptions 
Trauma or Immobility 
Hypercoagulability  
 
49 (59.8%) 
13 (16.3%) 
2 (2.5%) 
8 (10.0%) 
9 (11.3%) 
PE — pulmonary embolism 
 
 
 
 
 
 
Table 2. Angiographic and procedural data. 
Angiographic data 
Thrombi location 
Proximal main branch and central  
Distal main branch  
Distal segment 
Thrombi side 
Right  
Left 
Both 
 
40 (50.0%) 
36 (45.0%) 
4 (5.0%) 
 
14 (17.5%) 
15 (18.8%) 
51 (63.8%) 
Procedural data 
Contrast consumption [mL] 
Fluoroscopy time [min] 
X-ray dose [dyn] 
Dose area product [dyn/cm2] 
Average lysis time [h] 
Technical success 
Procedural technique 
Catheter directed thrombolysis 
Additional thrombectomy 
Prolonged thrombolysis ( 24 h) 
Balloon dilatation 
 
64.2 ± 26.3 
4.77 ± 1.9 
358.1 ± 170.1 
2.7 ± 1.6 
27.8 ± 9.6 
79 (98.8%) 
 
80 (100.0%) 
12 (15.0%) 
16 (20.0%) 
2 (2.5%) 
Invasive pulmonary pressure [mmHg] 
Before thrombolysis 
First postoperative day 
Second postoperative day or FINAL pressure 
 
57.5 ± 16.7 
39.9 ± 39.9 
38.9 ± 13.5 
*p < 0.01 
 
 
Table 3. Echocardiographic parameters. 
ECHO Preinterventional 
(n = 80) 
Post interventional 
(n = 80) 
One-year follow-
up (n = 74) 
P 
LVEF [%] 
PP  
D sign: 
- 0 
- 1 
RV/LV: 
- < 1 
- 1 
- > 1 
TAPSE  
57 53–60 
55 46–66 
 
 
 
4 (5.0%) 
76 (95.0%) 
4 (5.0%) 
21 (26.3%) 
55 (68.8%) 
18 [16–20] 
58 54–60 
40 40–48 
 
 
 
75 (93.8%) 
5 (6.2%) 
51 (63.8%) 
24 (30.0%) 
5 (6.3%) 
22 [20–24] 
60 56–60 
35 30–40 
 
 
 
76 (95.0%) 
4 (5.0%) 
71 (95.9%) 
0 (0.0%) 
3 (4.1%) 
24 [22–27] 
< 0.001 
< 0.001 
< 0.001 
 
 
< 0.001 
 
 
 
0.005 
LV — left ventricle; LVEF — left ventricular ejection fraction; RV — right ventricle; PP — pulmonary 
pressure; TAPSE — tricuspid annular plane systolic excursion 
 
 
Table 4. Procedural complications and major adverse events (MAE). 
 One-month follow-up One-year follow-up 
Summary of MAE 
Cardiovascular death  
Intracranial bleeding 
Myocardial infarction 
Repeat revascularization 
All MAE’s  
Death (all) 
 
0 (0%) 
1 (1.2%) 
0 (0%) 
0 (0.0%) 
1 (1.2%) 
1 (1.2%) 
 
1 (1.4%) 
2 (2.7%) 
0 (0%) 
1 (1.3%) 
3 (4.0%) 
5 (6.7%) 
Periprocedural complication 
Respiratory failure 
Cardiogenic shock 
Stroke/Cerebral bleeding 
 
0 (0%) 
0 (0%) 
1 (1.2%) 
 
- 
- 
- 
Pulmonary vascular complications 
Perforation 
Major distal embolization 
 
0 (0%) 
0 (0%) 
 
- 
- 
Bleeding complications 
Intracranial bleeding 
Access site complications 
Major 
Minor 
All bleeding complications 
 
1 (1.2%) 
 
6 (7.5%) 
6 (7.5%) 
13 (16.2%) 
 
2 (2.7%) 
 
6 (7.5%) 
6 (7.5%) 
13 (16.2%)  
 
FIGURE 1. Angiography and catheter directed thrombolysis of a 63-year-old woman 
presenting with acute dyspnea and referred for pulmonary angiography; A. Selective 
angiography from right femoral vein access shows nearly complete left main pulmonary 
artery occlusion and elevated pulmonary pressures. Selective thrombolysis with 10 mg tPa, 
followed by 1 mg/h- maintained infusion was initiated; B. Control angiography shows 
complete resolution of the thrombi and decreased pulmonary pressure.  
FIGURE 2. Catheter directed thrombolysis and mechanical thrombectomy of a 68-year-old 
man presenting with acute dyspnea; A. Selective angiography from right femoral vein access 
shows nearly complete right main pulmonary artery occlusion and elevated systolic 
pulmonary pressure (70 mmHg). Selective thrombolysis with 10 mg tPa, followed by 1 mg/h- 
maintained infusion was initiated; B. Control angiography shows incomplete thrombus 
resolution and hemodynamic result (systolic pulmonary pressure: 70 mmHg), therefore a 7 F 
90 cm sheath was advanced in the right main pulmonary artery over a long 360 J tip 
guidewire (C) and mechanical thrombectomy was done with a 100 cm Judkins right guiding 
catheter (D); E. Control angiography shows complete resolution of the thrombi and decreased 
systolic pulmonary pressure (40 mmHg).  
FIGURE 3. Invasive pulmonary pressures before and after thrombolysis. 



